Professor Shimon Slavin | |
|---|---|
 | |
| Born | May 17, 1941 |
| Education | Hebrew University of Jerusalem
Stanford University School of Medicine Fred Hutchinson Cancer Research Center |
| Occupation(s) | Medical Director of Biotherapy International, The Center for Innovative Cancer Biotherapy & Regenerative Medicine, medical director at Superinfection |
| Medical career | |
| Profession | Cancer immunotherapy, clinical immunology, regenerative medicine |
| Sub-specialties | Internal medicine, clinical immunology and allergy |
Shimon Slavin (born 17 May 1941) is an Israeli professor of medicine. He pioneered immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation to cure hematological malignancies and solid tumors. He also used hematopoietic stem cells to induce transplantation tolerance to bone marrow and organ allografts.
More recently, he has been working on the use of multi-potent mesenchymal stem cells (MSCs) in regenerative medicine for the treatment of neurological, systemic, and orthopedic disorders.
He is currently serving as the medical and scientific director of Biotherapy International Center for Innovative Cancer Immunotherapy & Cellular Medicine in Tel Aviv, Israel,[1][2] and as the medical director at Superinfection, a biotechnology company in Budapest, Hungary.[3]
- ^ "Prof. Shimon Slavin, MD". Open Health Alliance (in Greek). Retrieved 2024-06-19.
- ^ "Prof. Slavin, Medical & Scientific Director of Biotherapy International". Retrieved 2023-05-17.
- ^ "Leadership - Superinfection Therapy". Retrieved 2023-05-17.